Brand Name

Ampyra

Generic Name
Dalfampridine
View Brand Information
FDA approval date: March 01, 2010
Classification: Potassium Channel Blocker
Form: Tablet

What is Ampyra (Dalfampridine)?

Dalfampridine extended-release tablet is indicated as a treatment to improve walking in adult patients with multiple sclerosis . This was demonstrated by an increase in walking speed. Dalfampridine extended-release tablet is a potassium channel blocker indicated to improve walking in adult patients with multiple sclerosis . This was demonstrated by an increase in walking speed .

Approved To Treat

Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

4-Aminopyridine to Treat Skin Burns

Summary: Many patients suffer from traumatic burns and current treatments do not increase the regenerative potential of either skin grafts or the remaining uninjured skin. There is a need to develop treatments to accelerate and improve healing of burn injuries. More research is needed to evaluate the role of 4-AP, a promising new agent with an excellent safety profile, on wound and burn healing. The invest...

Dalfampridine Combined With Physical Therapy for Mobility Impairment in People With Multiple Sclerosis

Summary: The goal of this clinical trial is to evaluate if combining a medication that can help improve walking in people with multiple sclerosis (MS) with a physical therapy program is better for improving walking than either treatment alone. The main questions this study will answer are: * Does combining dalfampridine with physical therapy improve mobility more than physical therapy without concurrent da...

4-aminopyridine Treatment for Nerve Injury Resulting From Radical Retro-Pubic Prostatectomy

Summary: To evaluate the role of 4-aminopyridine (4-AP) on the course of recovery after peripheral nerve traction and/or crush injury. This study aims to test the hypothesis that 4-aminopyridine speeds the often slow and unpredictable recovery after peripheral nerve traction and/or crush injuries.